Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Shouse

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Blood Advances|November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC ConsortiumJohn Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Blood Advances|February 23, 2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphomaJuan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Blood Advances|November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC ConsortiumJohn Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Blood Advances|February 23, 2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphomaJuan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 6